References
- Sorkness CA, Wildfire JJ, Calatroni A, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immumol Pract 2013;160:102–110.
- Kallieri M, Papaioannou A, Papathanasiou E, et al. Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life study. Postgrad Med 2017;129:598–604.
- National Institute for Health and Care Excellence (2017) Mepolizumab for treating severe refractory eosinophilic asthma. NICE technology appraisal guidance (TA431).
- Scottish Medicine Consortium (2016) Mepolizumab 100mg powder for solution for injection (Nucala®). SMC No. (1149/16).
- Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo controlled trial. Lancet 2012;380:651–659.
- Ortega HG, Liu M, Pavord I, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198–1207.
- Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189–1197.
- GlaxoSmithKline. European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma. London, UK: GlaxoSmithKline; 30 Aug 2018. Available from: https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-nucala-mepolizumab-for-the-treatment-of-children-with-severe-asthma/ [last accessed September 2018].
- GSK Clinical Study Report MEA115588. Available from: https://www.gsk-clinicalstudyregister.com/files2/gsk-115588-clinical-study-report-redact.pdf [last accessed July 2018].
- GSK Clinical Study Report MEA 115575. Available from: https://www.gsk-clinicalstudyregister.com/files2/gsk-115575-clinical-study-report-redact.pdf [last accessed July 2018].
- GSK Clinical Study Report MEA112997. Available from: https://www.gsk-clinicalstudyregister.com/files2/gsk-112997-clinical-study-report-redact.pdf [last accessed July 2018].
- Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113:59–65.
- National Institute for Health and Care Excellence (2013) Omalizumab for treating severe persistent allergic asthma. NICE technology appraisal guidance (TA278).
- Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319–339.
- Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005;26:511–522.
- Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM, Brusasco V, Burgos F, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720–735.
- Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012;40:1324–1343.
- Halder P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973–984.
- Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013;132:821–827.